Safety of peginterferon alfa-2a (40KD) treatment in patients with chronic hepatitis B infection: An observational, multicenter, open label, non-interventional study in Turkish patients

Sadeleştirilmiş öğe sayfası
dc.contributor.authorTozun, Nurdan
dc.contributor.authorSezgin, Orhan
dc.contributor.authorGulsen, Murat
dc.contributor.authorKacar, Sabite
dc.contributor.authorYenice, Necati
dc.contributor.authorYilmaz, Serif
dc.contributor.authorHulagu, Saadettin
dc.contributor.authorKantarceken, Bulent
dc.contributor.authorYakaryilmaz, Fahri
dc.contributor.authorYurci, Alper
dc.contributor.authorSerez, Kemal Mustafa
dc.contributor.authorBahcecioglu, Halil
dc.contributor.authorBagci, Sait
dc.date.accessioned2025-10-16T15:35:30Z
dc.date.issued2012
dc.identifier.doi10.4318/tjg.2012.0410
dc.identifier.otherWOS:000311871900019
dc.identifier.urihttps://openaccess.acibadem.edu.tr/handle/11443/9482
dc.publisherAVES
dc.sourceTURKISH JOURNAL OF GASTROENTEROLOGY
dc.subjectPeginterferon alfa\\-2a
dc.subjectHBV infection
dc.subjectsafety
dc.subjectpatient compliance
dc.subjecttolerability
dc.subjectreal\\-life practice
dc.titleSafety of peginterferon alfa-2a (40KD) treatment in patients with chronic hepatitis B infection: An observational, multicenter, open label, non-interventional study in Turkish patients
dc.typeArticle

Dosyalar

Koleksiyonlar

WOS